Education
About Us
Working with TipRanks
Follow Us
Rapport Therapeutics, Inc. (RAPP)
:RAPP
Total Valuation
Rapport Therapeutics, Inc. has a market cap or net worth of $441.62M. The enterprise value is $729.63M.
Market Cap$441.62M
Enterprise Value$729.63M
Share Statistics
Rapport Therapeutics, Inc. has 36,497,555 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding36,497,555
Owned by Insiders39.69%
Owned by Institutions0.03%
Financial Efficiency
Rapport Therapeutics, Inc.’s return on equity (ROE) is -0.26 and return on invested capital (ROIC) is -27.06%.
Return on Equity (ROE)-0.26
Return on Assets (ROA)-0.25
Return on Invested Capital (ROIC)-27.06%
Return on Capital Employed (ROCE)-0.27
Revenue Per Employee0.00
Profits Per Employee-1.13M
Employee Count69
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Rapport Therapeutics, Inc. is -46.98. Rapport Therapeutics, Inc.’s PEG ratio is 0.00.
PE Ratio-46.98
PS Ratio0.00
PB Ratio39.00
Price to Fair Value12.05
Price to FCF-215.77
Price to Operating Cash Flow-234.67
PEG Ratio0.00
Income Statement
In the last 12 months, Rapport Therapeutics, Inc. had revenue of 0.00 and earned -78.31M in profits. Earnings per share was -0.38.
Revenue0.00
Gross Profit0.00
Operating Income-83.06M
Pretax Income-78.31M
Net Income-78.31M
EBITDA-77.47M
Earnings Per Share (EPS)-0.38
Cash Flow
In the last 12 months, operating cash flow was -67.45M and capital expenditures -1.62M, giving a free cash flow of -69.07M billion.
Operating Cash Flow-67.45M
Free Cash Flow-69.07M
Free Cash Flow per Share-1.89
Dividends & Yields
Rapport Therapeutics, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.34
52-Week Price Change-54.16%
50-Day Moving Average10.47
200-Day Moving Average16.19
Relative Strength Index (RSI)50.44
Average Volume (3m)188.78K
Important Dates
Rapport Therapeutics, Inc. upcoming earnings date is Aug 7, 2025, TBA Not Confirmed.
Last Earnings DateMay 8, 2025
Next Earnings DateAug 7, 2025
Ex-Dividend Date―
Financial Position
Rapport Therapeutics, Inc. as a current ratio of 35.34, with Debt / Equity ratio of 0.00%
Current Ratio35.34
Quick Ratio35.34
Debt to Market Cap<0.01
Net Debt to EBITDA0.71
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Rapport Therapeutics, Inc. has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Rapport Therapeutics, Inc. EV to EBITDA ratio is -46.78, with an EV/FCF ratio of -53.90.
EV to Sales0.00
EV to EBITDA-46.78
EV to Free Cash Flow-53.90
EV to Operating Cash Flow-55.90
Balance Sheet
Rapport Therapeutics, Inc. has $285.38M in cash and marketable securities with $7.84M in debt, giving a net cash position of -$277.54M billion.
Cash & Marketable Securities$285.38M
Total Debt$7.84M
Net Cash-$277.54M
Net Cash Per Share-$7.60
Tangible Book Value Per Share$1.47
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Rapport Therapeutics, Inc. is $35.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$35.00
Price Target Upside189.26% Upside
Analyst ConsensusStrong Buy
Analyst Count4
Revenue Growth Forecast―
EPS Growth Forecast―